Navigation Links
Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody
Date:10/2/2008

Data Indicate Dual Modes of Action and Synergy with Chemotherapy

DALLAS, Oct. 2 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) presented data this week from preclinical studies on Angiolix showing that by blocking lactadherin, Angiolix has both an anti-angiogenic effect as well as a direct anti-proliferative effect on tumors themselves. In preclinical models of human breast cancer (MX-1), Angiolix had a significant anti-cancer effect in vivo; this effect was enhanced when Angiolix was given in combination with conventional chemotherapy for breast cancer. The studies were conducted at Imperial College London and presented at the International Conference titled "Realizing the Commercial Potential of Therapeutic Antibodies," held in London, UK.

"We are delighted with these results which demonstrate the substantial anti-cancer effect of Angiolix, which we feel is comparable to Avastin yet achieved through a different and potentially complementary mechanism of action," stated Jeffrey B. Davis, President & CEO. "As stated previously, Access is actively seeking potential partners for the further clinical development of Angiolix."

"Angiolix is highly tumor specific," continued Agamemnon Epenetos, Chief Scientific Officer, Europe, "because the target lactadherin is primarily found in tumors and not in normal tissues. Other targets, such as VEGF, are present in many normal tissues; the blocking of VEGF may contribute to side effects such as high blood pressure and bleeding episodes, for example. Angiolix appears to be a more tumor selective anti-angiogenesis monoclonal antibody, with the benefit of having anti-proliferative activity."

Access is continuing to conduct pre-clinical studies at Imperial College London to more fully define the safety and efficacy profile of Angiolix.

About Angiolix:

Angiolix is a novel humanized monoclonal antibody which has considerable potential for the treatment of cancer through its affinity for a novel target, lactadherin. Lactadherin is an extracellular matrix protein that is released by numerous types of tumor cells, including most breast cancers, ovarian cancers and prostate cancer. Lactadherin has a critical role in promoting the growth of new blood vessels to support tumor growth through the activation of VEGF-mediated angiogenesis. The target lactadherin and Angiolix are supported and protected by granted patents.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , Jan. 23, 2017  Allergan plc, (NYSE: ... continued support of the International Headache Academy (IHA). Designed to ... and research scientists, IHA offers a three-day, intensive overview on ... Allergan has been the sole sponsor since the inception of ... and iHEAD in Europe in 2014. ...
(Date:1/23/2017)... 23, 2017 Ahead of today,s trading session, ... they have fared at the close: Kite Pharma Inc. (NASDAQ: ... OVAS ), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ... relative laggards on Friday, January 20 th , 2017, down on ... reports on these stocks now at: ...
(Date:1/23/2017)... SAN DIEGO , 23 janvier 2017  ResMed ... Winter Haven , Floride) ont annoncé aujourd,hui qu,ils se ... les litiges existants entre les parties. BMC et 3B ... de paiements de droits à ResMed, et ResMed effectuera ... à 3B pour clore le litige de Floride entre ...
Breaking Medicine Technology:
(Date:1/24/2017)... TEXAS (PRWEB) , ... January ... ... Texas-based healthcare and clinical research networking-technology company founded by patient survivors, today ... innovative BlueCloud® business model, networking technologies and patient-inspired initiatives. , Like ...
(Date:1/24/2017)... ... 23, 2017 , ... United Nations Foundation President and CEO ... City Policy, also known as the Global Gag Rule, last enacted in 2001. ... non-governmental organizations from receiving any U.S. foreign assistance for family planning if they ...
(Date:1/24/2017)... , ... January 23, 2017 , ... ... of a new plugin that allows sleep centers to automatically connect and initialize ... (SDI)—is a thin client browser plugin is quickly installed on first use and ...
(Date:1/23/2017)... ... January 23, 2017 , ... Ultimate Medical ... Education Summit to be held March 23-25, 2017 in Tampa, and reminded educators ... , The keynote speakers include Dr. Michelle R. Weise, executive director of the ...
(Date:1/23/2017)... Grants Pass, OR (PRWEB) , ... January 23, 2017 , ... ... disease, took to the air to educate listeners about the benefits of making new ... in the U.S.,” Kleyne said, “it’s appropriate that we expect water infrastructure to become ...
Breaking Medicine News(10 mins):